Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Next Previous
X
Search
Trial Profile

A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMG 199 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Adverse reactions; First in man
  • Sponsors Amgen

    • Most Recent Events

    • 19 Jun 2023 Status changed from active, no longer recruiting to discontinued as per business decision.
    • 28 Mar 2023 Planned End Date changed from 19 May 2023 to 1 Jun 2023.
    • 28 Mar 2023 Planned primary completion date changed from 19 May 2023 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top